Headlines about Zoetis (NYSE:ZTS) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zoetis earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.4768988193003 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Critical Comparison: Zoetis (ZTS) & Cara Therapeutics (CARA) (americanbankingnews.com)
- Zoetis Inc. (ZTS) stock exposed movement of 0.08% for the previous five trading days – Analyst Recommendation (press release) (blog) (analystrecommendation.com)
- Morgan Stanley Downgrades Zoetis Inc. (ZTS) to Equalweight – StreetInsider.com (streetinsider.com)
- Anterra Capital Expands Fund to $200M (prweb.com)
- Zoetis Inc (ZTS) Insider Heidi C. Chen Sells 7,383 Shares (americanbankingnews.com)
Several equities research analysts recently weighed in on the stock. Morgan Stanley upgraded shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target on the stock in a research report on Wednesday, November 29th. Citigroup upgraded shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price target on the stock in a research report on Thursday, January 4th. UBS restated a “neutral” rating on shares of Zoetis in a research report on Friday, November 24th. Cantor Fitzgerald set a $85.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Thursday, January 11th. Finally, Jefferies Group set a $97.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Monday, February 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $79.72.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 15th. The company reported $0.69 EPS for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.03. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.47 earnings per share. equities research analysts expect that Zoetis will post 3.04 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date is Thursday, April 19th. Zoetis’s payout ratio is presently 28.57%.
In related news, insider Roman Trawicki sold 8,568 shares of the company’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $83.10, for a total value of $712,000.80. Following the completion of the sale, the insider now directly owns 11,457 shares of the company’s stock, valued at $952,076.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Heidi C. Chen sold 7,383 shares of the company’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $84.71, for a total transaction of $625,413.93. Following the completion of the sale, the insider now directly owns 20,162 shares of the company’s stock, valued at $1,707,923.02. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 112,952 shares of company stock worth $9,219,843. Company insiders own 0.31% of the company’s stock.
WARNING: “Zoetis (NYSE:ZTS) Earning Somewhat Favorable Media Coverage, Analysis Finds” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/2018/03/22/zoetis-zts-earning-somewhat-positive-press-coverage-report-shows/1926955.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.